Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction "CHARM"

Not yet recruiting

Phase 3 Results N/A

Summary of Purpose

This study evaluates the use of the investigational drug BIIB093 versus placebo in patients with a large hemispheric infarction.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 20 March 2018.

29 Jun 2018 12 Jul 2016 28 Sep 2020 28 Jun 2021 1 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts